Ivermectin: An assessment of its pharmacology, microbiology and safety

Veterinary and Human Toxicology

Volumn 42, Issue 1, 2000, Pages 30-35

  Burkhart, Craig N ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IVERMECTIN;

ANTIBIOTIC RESISTANCE; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG SAFETY; PARASITOSIS; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; ANTHELMINTICS; BIOLOGICAL AVAILABILITY; DRUG RESISTANCE; HALF-LIFE; HUMANS; IVERMECTIN;

INVERTEBRATA;

EID: 0033968459     PISSN: 01456296     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Fisher MH, Mrozik H: Chemistry. In Campbell WC ed: Ivermectin and Abamectin. Springer-Verlag, New York 1-23, 1989.
2. Meinking TL: Parasites. In James R ed: Current Problems in Dermatology. Mosby, New York 11:73-114, 1999.
3. Edwards G, Breckenridge AM: Clinical pharmacokinetics of anthelmintic drugs. Clin Pharmacokinetics 15:67-93, 1988.
4. Ette EI, Thomas WOA, Achumba JI: Ivermectin: a long-acting microfilaricidal agent. Annals Pharmacotherapy 24:426-433, 1990.
5. Chiu SHL, Lu AYH: Metabolism and tissue residues. In Campbell WC ed: Ivermectin and Abamectin. Springer-Verlag, New York 131-143, 1989.
6. th International Congress. Blackwell Scientific Publications, Edinburgh 275-276, 1994.
7. Chiu SHL, Taub R, Sestokas E et al: Comparative in vivo and in vitro metabolism of ivermectin in steer, sheep, swine, and rat. Drug Metabolism Rev 18:289-302, 1987.
8. Halley BA, Nessel RJ, Lu AYH: Environmental aspects of ivermectin usage in livestock: general considerations. In Campbell WC ed: Ivermectin and Abamectin. Springer-Verlag, New York 162-172, 1989.
9. Oukessou M, Berrag B, Alvinerie M: A comparative kinetic study of ivermectin and moxidectin in lactating camels (Camelus dromedarius). Veter Parasitol 83:151-159, 1999.
10. Toutain PL, Alvinerie M, Galtier P: Plasma and milk kinetics of therapeutic doses of ivermectin for dairy cows. In Simon E ed: Veterinary Pharmacology, Toxicology and Therapy in food-producing animals. Budapest University Press, Budapest, Hungary: 334-336, 1988.
11. Ogbuokiri JE, Ozumba BC, Okonwo PO: Ivermectin levels in human breast milk. Eur J Clin Pharmacol 46:89-90, 1994.
12. Pusterla N, Caplazi P, Lutz H et al: Investigations on the treatment of cerebrospinal nematode infections in goats. Deutsche Tierarztliche Wochenschrift 106:22-24, 1999.
13. Marriner SE, McKinnon I, Bogan JA: The pharmacokinetics of ivermectin after oral and subcutaneous administration to sheep and horses. J Vet Pharmacol Ther 10:175-179, 1987.
14. Chiu S, Green M, Baylis F et al: Absorption, tissue distribution, and excretion of tritium-labelled ivermectin in cattle, sheep, and rat. J Agriculture Food Chem 38:2072-2078, 1990.
15. Fink DW, Porras AG: Pharmacokinetics of ivermectin in animals and humans. In Campbell WC ed: Ivermectin and Abamecin. Springer-Verlag, New York 113-130, 1989.
16. Prichard RK, Steel JW, Lacey E et al: Pharmacokinetics of ivermectin in sheep following intravenous, intra-abomasal or intraruminal administration. J Vet Pharmacol Ther 8:88-91, 1985.
17. Scott EW, Kinabo LD, McKellar QA: Pharmacokinetics of ivermectin after oral or percutaneous administration to adult milking goats. J Vet Pharmacol Ther 13:432-435, 1990.
18. Miller JA, Oehler DD, Pound JM; Delivery of ivermectin by injectable microspheres. J Econ Entomol 91:655-659, 1998.
19. Edwards G, Dingsdale A, Helsby N et al: The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution. Eur J Clin Pharmacol 35:681-684, 1988.
20. Liu L, Weller PF: Drug therapy: antiparasitic drugs. N Engl J Med 334:1178-1184, 1996.
21. Nutman TB, Nash TE, Ottesen EA: Ivermectin in the successful treatment of a patient with Mansonella ozzardi infection. J Infect Dis 156:662-665, 1987.
22. Drugs for parasitic infections. Med Lett Drugs Ther 37:99-108, 1995.
23. Martin-Prevel Y, Cosnefroy JY, Tshipamba P et al: Tolerance and efficacy of single high-dose ivermectin for the treatment of loiasis. Am J Top Med Hyg 48:186-192, 1993.
24. Naquira C, Jimenez G, Guerra JG: Ivermectin for human strongyloidiasis and other intestinal helminths. Am J Top Med Hyg 40:304-309, 1989.
25. Caumes E, Carriere J, Datry A et al: A randomized trial of ivermectin versus thiabendazole for treatment of strongyloidiasis. Am J Top Med Hyg 49:641-644, 1993.
26. Gann PH, Neva FA, Gam AA: A randomized trial of single- and two dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J Infect Dis 169:1076-1079, 1994.
27. Datry A, Hilmarsdottir I, Mayorga-Sagastume R: Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 cases. Trans R Soc Trop Hyg 88:344-345, 1994.
28. Meinking TL, Taplin D, Herminda JL et al: The treatment of scabies with ivermectin. N Engl J Med 333:26-30, 1995.
29. Aubin F, Humbert P: Ivermectin for crusted (Norwegian) scabies. N Engl J Med 332:612, 1995.
30. Dunne CL, Malone CJ, Whitworth JA: A field study of the effects of ivermectin on ectoparasites of man. Trans R Soc Trop Med Hyg 85:550-551, 1998.
31. Glaziou P, Cartel JL, Alzieu P et al: Comparison of ivermectin and benzyl benzoate for treatment of scabies. Trop Med Parasitol 44:331-332, 1993.
32. Burkhart CG, Burkhart CN: An assessment of the topical and oral, prescription and over-the-counter treatments for head lice. J Am Acad Dermatol 38:979-982, 1998.
33. Cupp EW: Treatment of onchocerciasis with ivermectin in Central America. Parasitol Today 8:212-214, 1992.
34. Torres JR, Isturiz R, Murillo J et al: Efficacy of ivermectin in the treatment of strongyloidiasis complicating AIDS. Clin Infect Dis 17:900-902, 1993.
35. Greene BM, Kukuly ZD, Munoz B et al: A comparison of 6-, 12-, and 24-monthly dosing with ivermectin for treatment of onchocerciasis. J Infect Dis 163:376-380, 1991.
36. Pacque M, Munoz B, Poetschke G et al: Pregnancy outcome after inadvertent ivermectin treatment during community-based distribution. Lancet 336:1486-1489, 1990.
37. Ottesen EA, Vijayasekaran V, Kumaraswami V: A controlled trial of ivermectin and diethylcarbamazine in lymphatic filariasis. N Engl J Med 322:1113-1117, 1990.
38. Mak JW, Navaratnam V, Grewel JS et al: Treatment of subperiodic Brugia malayi infection with a single dose of ivermectin. Am J Trop Med Hyg 48:591-596, 1993.
39. Kazura J, Green berg J, Perry R et al: Comparison of single-dose diethylcarbamazine and ivermectin for treatment of Bancroftian filariasis in Papua, New Guinea. Am J Trop Med Hyg 49:804-811, 1993.
40. Burkhart CG, Burkhart CN: An epidemiologic and therapeutic reassessment of scabies: special focus on fomite transmission and the newly available ivermectin oral treatment. Cutis (in press).
41. Meinking TL, Burkhart CG, Burkhart CN: Ectoparasitic diseases in dermatology: reassessment of scabies and pediculosis. In James W ed: Advances in Dermatology. Mosby, New York 15:44-80, 1999.
42. Youssef MYM, Sadaka HAH, Eissa MM et al: Topical application of ivermectin for human ectoparasites. Am J Torp Med Hyg 53:652-653, 1995.
43. Howells RE: Filariae: Dynamics of the surface. In Vanden Bossche H ed: The Host-Invader Interplay. Elsevier, North-Holland, Amsterdam 69-84, 1980.
44. Court JP, Murgatroyd RC, Livingstone D et al: Physicochemical characteristics of non-electrolytes and their uptake by Brugla pahangi and Dipetalonema viteae. Mol Biochem Parasitol 38:183-227, 1988.
45. Mrozik H, Linn BO, Eskala P: Synthesis and biological activities of 13-substituted avermectin aglycones. J Med Chem 32:375-381, 1989.
46. th Biennial symposium. American Academy of Veterinary Pharmacology and Therapeutics, Kalamazoo, Michigan 35-51, 1994.
47. Fraser SP, Djamgoz MB, Usherwood PN et al: Amino acid receptors from insect muscle: electrophysiological characterization in Xenopus oocytes following expression by injection of mRNA. Mol Brain Res. 8:331-341, 1990.
48. Duce IR, Scott RH: Actions of dihydroavermectin B1a on insect muscle. Br J Pharmacol 85:395-401, 1985.
49. Scott RH, Duce IR: Anion selectivity of gamma-aminobutyric acid (GABA) 22,23-dihydroavermectin B1a (DHAVM)-induced conductance changes on locust muscle. Neurosci Lett 68:197-201, 1986.
50. Paiement J, Prichard RK, Ribeiro P: Haemonchus contortus: characterization of a glutamate binding site in unselected and ivermectin-selected larvae and adults. Experimental Parasitol 92:32-9, 1999.
51. Schaeffer JM, Haines HW: Avermectin binding in Caenorhabditis elegans. A two-state model for the avermectin binding site. Biochem Pharmacol. 38:2329-2338, 1989.
52. Martin RJ: An electrophysiological preparation of Ascaris suum pharyngeal muscle reveals a glutamate-gated chloride channel sensitive to the avermectin analogue, milbemycin D. Parasitol. 112:247-252, 1996.
53. Cully DF, Vassilatis DK, Liu KK et al: Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans. Nature 371:707-11, 1994.
54. Etter A, Cully DF, Schaeffer JM et al: An amino acid substitution in the pore region of a glutamate-gated chloride channel enables the coupling of ligand binding to channel gating. J Biol Chem 271:16035-16039, 1996.
55. Vassilatis DK, Arena JP, Plasterk RHA et al: Genetic and biochemical evidence for a novel avermectin-sensive chloride channel in Caenorhabditis elegans. J Biol Chem 272:33167-33174, 1997.
56. Arena JP, Liu KK, Paress PS et al: Expression of a glutamate-activated chloride current in Xenopus oocytes injected with Caenorhabditis elegans RNA: evidence for modulation by avermectin. Brain Research. Mol Brain Res 15:339-348, 1992.
57. Dent JA, Davis MW, Avery L: Avr-15 encodes a chloride channel subunit that mediates inhibitory glutamatergic neurotransmission and ivermectin sensitivity in Caenorhabditis elegans. EMBO J 16(19):5867-5879, 1997.
58. Blackhall WJ, Pouliot JF, Prichard RK et al: Haemonchus contortus: selection at a glutamate-gated chloride channel gene in ivermectin- and moxidectin-selected strains. Exp Parasitol 90:42-48, 1998.
59. Ros-Moreno RM, Moreno-Guzman MJ, Jimenez-Gonzalez A et al: Interaction of ivermectin with c-aminobutyric acid receptors in Trichinella spiralis muscle larvae. Parasitol Res 85:320-3, 1999.
60. Zahner H, Schmidtchen D, Mutasa JA: Ivermectin-induced killing of microfilariae in vitro by neutrophils mediated by nitric oxide. Exp Parasitol 86:110-117, 1997.
61. Njoo FL, Hack CE, Oosting J et al: Neutrophil activation in ivermectin-treated onchocerciasis patients. Clin Exp Immunol 94:330-333, 1993.
62. Roa UR, Chandrashekar F, Subrahmanyam D: Effect of ivermectin on serum dependent cellular interactions to Dipetalonema viteae microfilariae. Trop Med Parasitol 38:123-127, 1987.
63. Zahner H, Schmidtchen D: Ivermectin-induced cell-dependent lethal effects on Litomosoides carinii microfilariae in vitro. Trop Med Parasitol 45:336-340, 1994.
64. Schinkel AH, Smit JJM, van Tellingen O et al: Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502, 1994.
65. Gros P, Croop J, Housman D: Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 47:371-380, 1986.
66. Chen C, Chin JE, Ueda K et al: Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein gene) from multidrug-resistant human cells. Cell 47:381-389, 1986.
67. Gill JH, Kerr CA, Shoop WL et al: Evidence of multiple mechanisms of avermectin resistance in Haemonchus contortus - comparison of selection protocols. Int J Parasitol 28:783-789, 1998.
68. Didier A, Loor F: The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor. Anti-Cancer Drugs 7:745-751, 1996.
69. Pouliot JF, L'heureux F, Liu Z et al: Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem Pharmacol 53:17-25, 1997.
70. Xu, M, Molento M, Blackhall W et al: Ivermectin resistance in nematodes may be cause by alteration of P-glycoprotein homolog. Mol Biochem Parasitol 91:327-335, 1998.
71. Blackhall WJ, Liu HY, Xu M et al: Selection at a P-glycoprotein gene in ivermectin- and moxidectin-selected strains of Haemonchus contortus. Mol Biochem Parasitol 95:193-201, 1998.
72. Broeks A, Janssen HW, Clafat J et al: A P-glycoprotein protects Caenorhabditis elegans against natural toxins EMBO J 14:1858-1866, 1995.
73. Broeks A, Gerrard B, Allikmets R et al: Homologue of the human multidrug resistance genes MRP and MDR contribute to heavy metal resistance in the soil nematode Caenorhabditis elegans. EMBO J 15:6132-6143, 1996.
74. Kwa MSG, Okoli MN, Schulz-Key H et al: Use of P-glycoprotein gene probes to investigate anthelmintic resistance in Haemonchus contortus and comparison with Onchocerca volvulus. Int J Parasitol 28:1235-1240, 1998.
75. Zalis MG, Wilson GM, Zhang Y et al: Characterization of the pfmdr2 gene for Plamodium falciparum. Mol Biochem Parasitol 62:83-92, 1993.
76. Rubio JP, Cowman AF: Plasmodium falciparum: the pfmdr2 protein is not overexpressed in chloroquine-resistant isolates of malaria parasites. Exp Parasitol 79:137-147, 1994.
77. Wellems TE, Pantan LJ, Gluzman IY et al: Cloroquine resistance no linked to mdr-like genes in a Plasmodium falciparum cross. Nature 345:253-255, 1990.
78. Barnes DA, Foote SJ, Galatis D et al: Selection for high-level chloroquine resistance results in deamplification of the pfmdr1 gene and increases sensitivity in mefloquine in Plasmodium falciparum. EMBO J 11:3067-3075, 1992.
79. Rohrer SP, Birzin ET, Eary CH et al: Ivermectin binding sites in sensitive and resistant Haemonchus contortus. J Parasitol 80:493-497, 1994.
80. Fisher MH, Mrozik H: The chemistry and pharmacology of avermectins. Ann Rev Pharmacol Tox 32:537-553, 1992.
81. Huang L, Burg R: The avermectin receptor of the American cockroach. Soc Neurosci. Abstract 9.9, 1986.
82. Turner MJ, Schaeffer JM: Mode of action of ivermectin. In Campbell WC, ed: Ivermectin and Abamectin. Springer-Verlag, New York 73-88, 1989.
83. Chiu SHL, Lu AYH: Metabolism and tissue residues. In Campbell WC, ed: Ivermectin and Abamecin. Springer-Verlag, New York 131-143, 1989.
84. Awadzi K, Opoku NO, Addy ET: The chemotherapy of onchocerciasis. XIX: the clinical and laboratory tolerance of high dose ivermectin. Trop Med Parasitol 46:131-137, 1995.
85. Campbell WC, Benz GW: Ivermectin: a review of efficacy and safety. J Vet Pharmacol Ther 7:1-16, 1984.
86. Lankas GR, Gordon LR: Toxicology. In Campbell WC, ed: Ivermectin and Abamectin. Springer-Verlag, New York 89-112.
87. Chung K, Yang CC, Wu ML et al: Agricultural avermectins: an uncommon but potentially fatal cause of pesticide poisoning. Ann Emerg Med 34:51-7, 1999.
88. Brokken ES, Barth D, Foster AG et al: Ivermectin: a new broad-spectrum antiparasitic agent for swine. In: Proceedings of the MSD AGVET Symposium on Recent Developments in the Control of Animal Parasites at the XXII World Veterinary Congress, Perth, Australia 239-258, 1983.
89. Hotson IK: The development of ivermectin as an antiparasitic agent in sheep. In: Proceedings of the MSD AGVET Symposium on Recent Developments in the control of animal parasites at the XXII World Veterinary Congress, Perth, Australia 42-48, 1983.
90. Leaning WHD, Roncalli RA, Brokken ES: The efficacy and safety evaluation of ivermectin: a new injectable antiparasitic agent for cattle. In: Proceedings of the MSD AGVET Symposium on Recent Developments in the control of animal parasites at the XXII World Veterinary Congress 25-41, 1983.
91. Schroder J, Swan GE, Barrick RA et al: Effect of ivermectin on the reproductive potential for breeding rams. J S African Vet Assoc 57:211-213, 1986.
92. Marques-Santos LF, Bernardo RR, DePaula EF et al: Cyclosporin A and trifluoperazine, two resistance-modulating agents, increase ivermectin neurotoxicity in mice. Pharmacol Toxicol 84:125-9, 1999.
93. Kwei GY, Alvaro RF, Chen Q et al: Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab Disposition 27:581-7, 1999.
94. Poul JM: Effects of perinatal ivermectin exposure on behavioral development of rats. Neurotoxicol Teratol 10:267-272, 1988.
95. Pulliam JD, Seward RL, Henry RT et al: Investigating ivermectin toxicity in collies. Vet Med 80:33-40, 1985.
96. Michaelis EK: Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging. Prog in Neurobiol 54:369-415, 1998.
97. Etter A, Cully DR, Schaeffer JM et al: An amino acid substitution in the pore region of a glutamate-gate chloride channel enables the coupling of ligand binding to channel gating. J Biol Chem 271:16035-16039, 1996.
98. Huang J, Casida JE: Avermectin B1a binds to high- and low-affinity sites with dual effects on the γ-aminobutyric acid-gated chloride channel of cultured cerebellar granule neurons. J Pharmacol Exp Ther 281:261-266, 1997.
99. Pong SS, Wang CC: The specificity of high affinity binding of avermectin B to mammalian brain. Neuropharmacol 19:311-317, 1980.
100. Friz LC, Wang CC, Gorio A: Avermectin B irreversibly blocks postsynaptic potentials at the lobster neuromuscular junction by reducing muscle membrane resistance. Proc Natl Acad Sci 76:2062-2066, 1979.
101. Zufall F, Franke C, Hatt H: The insecticide avermectin B activates a chloride channel in crayfish muscle membrane. J Exp Biol 142:191-205, 1989.
102. Robertson B: Actions of anaesthetics and avermectin on GABA chloride channels in mammalian dorsal root ganglion neurons. J Pharmacol 98:167-176, 1989.
103. Schonrock B, Bormann J: Activation of Cl-channels by avermectin in rat cultured hippocampal neurons. Naunyn-Schmiedeberg's Arch Pharmacol 348:628-632, 1993.
104. Sigel E, Baur R: Effect of avermectin B on chick neuronal γ-aminobutyrate receptor channel expressin Xenopus oocytes. Mol Pharmacol 32:749-752, 1987.
105. Krause RM, Buisson B, Bertrand S et al: Ivermectin: a positive allosteric effector of the α7 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 53:283-302, 1998.
106. Wevers A, Sullivan JP, Giordano T et al: Cellular distribution of the mRNA for the alpha 7 subunit of the nicotinic acetylcholine receptor in the human cerebral cortex. Drug Dev Res 36:103-110, 1995.
107. Gray R, Rajan AS, Radcliffe KA et al: Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 383:713-716, 1996.
108. Lena C, Changeux JP: Role of calcium ions in nicotinic facilitation of GABA release in mouse thalamus. J Neurosci 17:576-585, 1997.